Lorediplon meets in Phase II insomnia trial

In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint in a Phase II trial to treat insomnia. Specifically, low-

Read the full 271 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE